Synergistic effect of sorafenib with ionizing radiation on human oral cancer cells

Fei Ting Hsu, Betty Chang, I. Tsang Chiang, Tai Hsien Wu, Jeng Jong Hwang

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)


Background/Aim: Although anticancer effects of sorafenib on renal, liver and colon carcinomas are wellknown, its combination effect with ionizing radiation on oral squamous cell carcinoma (OSCC) is unclear. Herein human SAS cells, an OSCC cell line, were used in order to elucidate this combination effect. Materials and Methods: Both SAS and SAS/nuclear factor kappa-B-luciferase (SAS/NF-κBluc2) cell lines were used in the study. Cell viability, NF-κB activation, and protein expression of NF-κB downstream effectors were determined by 3-(4,5-dimethylthiazol-2-yl)- 2,5-diphenyltetrazolium bromide assay, NF-κB-luc2 reporter gene system, NF-κB/DNA binding activity and western blotting. Results: Sorafenib significantly increased radiationinduced cytotoxicity and apoptosis via both mitochondrialdependent and independent pathways. In addition, NF-κB activity and downstream effector protein expression induced by radiation was suppressed by sorafenib in SAS/NF-κB-luc2 cells. Conclusion: Combination of sorafenib with radiation for the treatment of human OSCC shows a synergistic effect via suppression of radiation-induced NF-κB activity and its regulated downstream effector proteins.

Original languageEnglish
Pages (from-to)925-934
Number of pages10
JournalIn Vivo
Issue number5
Publication statusPublished - Sept 1 2014
Externally publishedYes


  • Human oral squamous cell carcinoma
  • NF-κB
  • Radiation
  • Sorafenib

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology


Dive into the research topics of 'Synergistic effect of sorafenib with ionizing radiation on human oral cancer cells'. Together they form a unique fingerprint.

Cite this